Results 81 to 90 of about 841 (115)

Design of RGD-functionalized GSH-responsive pegylated polymeric protacs for selective BRD4 degradation and EndMT-driven cardiac fibrosis inhibition. [PDF]

J Nanobiotechnology
Bi T, Chen L, Wang T, Miao W, Zhai S, Huang R, Sun Q, Chen Y, Su H, Zhou J, Li R, Huang W, Yao X, Luo P, Liu Z.   +14 more
europepmc   +1 more source

Diastereomeric Branched-Ester dBET1 Analogs Exhibit Conformation-Dependent Differences in Passive Membrane Permeability. [PDF]

J Med Chem
Abdelwahid MAS, Hayakawa E, Hirai K, Ishii M, Kanamitsu K, Yasuda S, Ohtake F, Sato S, Tomoshige S, Ishikawa M.   +9 more
europepmc   +1 more source

Highly efficient and long-acting split-and-mix proteolysis targeting chimera based on self-assembled polylactic acid. [PDF]

Nat Commun
Zhan MM, Chen H, He M, Song C, Jiao Z, Liu N, Liu Z, Hou Z, Chen Y, Song Z, Xing Y, Li Z, Yin F.   +12 more
europepmc   +1 more source

Second-Generation AURKA-Targeting PROTACs: Structural Optimization toward in Vivo Degradation in Neuroblastoma. [PDF]

J Med Chem
Krols S, Rishfi M, Martens F, Van Hauwermeiren A, Sanders E, De Sutter PJ, Vermeulen A, De Wever K, Bekaert SL, Dolman MEM, Tax G, Kamili A, Fletcher JI, Depestel L, De Wilde B, Durinck K, Van Calenbergh S.   +16 more
europepmc   +1 more source

PROTAC repurposing uncovers a noncanonical binding surface that mediates chemical degradation of nuclear receptors. [PDF]

Nat Commun
Huber AD, Lin W, Jung YH, Poudel S, Yang G, Wu J, Carrigan AG, Pagala V, Wang W, Fu Y, Yuan ZF, Byrum SD, Yang K, Gee RRF, Arnold ED, Loughran AJ, Wang J, Pruett-Miller SM, Peng J, Chen T.   +19 more
europepmc   +1 more source

Indoleamine 2,3-dioxygenase 1 in cancer immunotherapy: from small-molecule inhibition to PROTAC-mediated degradation. [PDF]

Front Pharmacol
Li X, Meng H, Wang H, Zhang Y, Yu W.
europepmc   +1 more source

Cysteine-reactive covalent chloro-N-acetamide ligands induce ferroptosis mediated cell death. [PDF]

EMBO Rep
Gotthardt G, Weckesser J, Tascher G, Barros da Gama S, Uckelmann HJ, Sun S, Schwalm MP, Mosler T, Ferrario G, Friedmann Angeli JP, Münch C, Knapp S, Müller S.   +12 more
europepmc   +1 more source

Conquering PROTAC molecular design and drugability. [PDF]

Bioanalysis
Bhole RP, Labhade S, Gurav SS.
europepmc   +1 more source

Prodrug Strategy for PROTACs: High Efficiency and Low Toxicity. [PDF]

ACS Omega
Li Y, Guo Y, Ma S, Long B, Kong R, Huang X, Zhao K, Zhi Y.   +7 more
europepmc   +1 more source